Daniel Rosan | Chief Business & Financial Officer
Ascidian Therapeutics

Daniel Rosan is an experienced biotech CBO & CFO and Board member. He serves as Chief Business and Financial Officer at Ascidian Therapeutics, a leading RNA editing company. Dan leads capital formation, partnering, finance, communications, and legal. He led Ascidian’s $1.8 B neurology collaboration with Roche. Over his career, Dan has supported four INDs, two BLAs, and multiple pioneering therapeutics; and has led many varieties of business and financial transactions, totaling >$ 5B. Prior to Ascidian, Dan led capital markets strategies and finance at Synlogic, a publicly traded synthetic biology company. He spent six years at Biogen in roles of increasing responsibility in Finance and Research & Development. Earlier in his career, Dan was a management consultant with Frankel Group (a boutique biotechnology firm acquired by Oliver Wyman), a public health advocate, and a community organizer. Dan holds a BA in History from Vassar College and an MBA from Harvard Business School. He lives in Somerville, Massachusetts with two children and not enough dogs.